Your browser doesn't support javascript.
loading
CM082 suppresses hypoxia-induced retinal neovascularization in larval zebrafish.
Zhang, Jun-Long; Fan, Ding-Gang; Yin, Wu; Hu, Bing.
Afiliación
  • Zhang JL; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
  • Fan DG; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
  • Yin W; Department of Geriatrics, Gerontology Institute of Anhui Province, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
  • Hu B; Anhui Province Key Laboratory of Geriatric Immunology and Nutrition Therapy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Front Pharmacol ; 15: 1336249, 2024.
Article en En | MEDLINE | ID: mdl-39135806
ABSTRACT
Retinal neovascularization is a common feature of several ocular neovascular diseases, which are the leading cause of blindness in the world. Current treatments are administered through invasive intravitreal injections, leading to poor patient compliance, serious ocular complications and heavy economic burdens. Thus, an alternative less or non-invasive therapeutic strategy is in demand. Here, a non-invasive oral tyrosine kinase inhibitor, CM082, was evaluated in a retinal neovascularization model induced by hypoxia in zebrafish larvae. We found that CM082 effectively suppressed retinal neovascularization, rescued cell loss in the retinal ganglion cell layer, and rescued the visual function deficiency. Our results elucidated that CM082 mediated its therapeutic efficacy primarily through the inhibition of Vegfr2 phosphorylation. The findings demonstrated that CM082 possessed strong antiangiogenic effects and may serve as a potential treatment for angiogenesis in ocular neovascular diseases.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: China